

Jorge Plutzky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5838968/publications.pdf>

Version: 2024-02-01

81
papers

6,090
citations

117625

34
h-index

71685

76
g-index

85
all docs

85
docs citations

85
times ranked

8768
citing authors

#	ARTICLE	IF	CITATIONS
1	PPAR δ Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. <i>Circulation</i> , 1999, 99, 3125-3131.	1.6	584
2	Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 1998, 83, 1097-1103.	4.5	565
3	NF- κ B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. <i>Molecular Cell</i> , 2014, 56, 219-231.	9.7	507
4	PPAR δ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 546-551.	2.4	355
5	Retinaldehyde represses adipogenesis and diet-induced obesity. <i>Nature Medicine</i> , 2007, 13, 695-702.	30.7	346
6	BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. <i>Cell</i> , 2013, 154, 569-582.	28.9	346
7	Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions. <i>Diabetes</i> , 2014, 63, 2578-2589.	0.6	185
8	Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR α -RXR complex. <i>FEBS Letters</i> , 2008, 582, 32-38.	2.8	180
9	Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 12.	4.7	180
10	PPAR δ Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes. <i>Circulation</i> , 2001, 103, 213-219.	1.6	177
11	Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. <i>Nature Medicine</i> , 2012, 18, 918-925.	30.7	176
12	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 292-302.	2.8	145
13	The PPAR-RXR Transcriptional Complex in the Vasculature. <i>Circulation Research</i> , 2011, 108, 1002-1016.	4.5	138
14	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020, 229, 61-69.	2.7	137
15	Diabetic Macrovascular Disease. <i>Circulation</i> , 2002, 106, 2760-2763.	1.6	121
16	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM δ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
17	Epigenetic Changes in Diabetes and Cardiovascular Risk. <i>Circulation Research</i> , 2016, 118, 1706-1722.	4.5	98
18	Retinaldehyde Dehydrogenase 1 Coordinates Hepatic Gluconeogenesis and Lipid Metabolism. <i>Endocrinology</i> , 2012, 153, 3089-3099.	2.8	94

#	ARTICLE	IF	CITATIONS
19	BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. <i>Circulation Research</i> , 2020, 126, 1190-1208.	4.5	88
20	MEDICINE: PPARs as Therapeutic Targets: Reverse Cardiology?. <i>Science</i> , 2003, 302, 406-407.	12.6	86
21	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , 2021, 235, 104-112.	2.7	82
22	Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes. <i>Annals of Internal Medicine</i> , 2017, 167, 221.	3.9	80
23	Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms. <i>Current Atherosclerosis Reports</i> , 2000, 2, 327-335.	4.8	77
24	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	2.3	75
25	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 401-415.	2.3	72
26	The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. <i>American Journal of Cardiology</i> , 2003, 92, 34-41.	1.6	70
27	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	2.8	69
28	BET bromodomain proteins regulate enhancer function during adipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2144-2149.	7.1	65
29	Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1430.	6.1	62
30	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	6.1	59
31	Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 564-571.	1.9	45
32	Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2015, 61, 155-161.	1.1	44
33	Digital Care Transformation. <i>Circulation</i> , 2021, 143, 507-509.	1.6	40
34	Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0155228.	2.5	37
35	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. <i>JAMA Cardiology</i> , 2021, 6, 880.	6.1	36
36	Inflammation in Atherosclerosis and Diabetes Mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 255-259.	5.7	35

#	ARTICLE	IF	CITATIONS
37	Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. American Journal of Cardiology, 2011, 108, 25B-32B.	1.6	35
38	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal, 2019, 40, 2907-2919.	2.2	32
39	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care, 2020, 43, 1843-1850.	8.6	27
40	Peroxisome Proliferator-Activated Receptors (PPARs) and Their Role in the Vessel Wall: Possible Mediators of Cardiovascular Risk?. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 203-210.	2.8	25
41	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. Global Heart, 2019, 14, 215.	2.3	24
42	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. Current HIV/AIDS Reports, 2021, 18, 271-279.	3.1	24
43	Statins for Stroke: The Second Story?. Circulation, 2001, 103, 348-350.	1.6	23
44	A Cardiologist's Perspective on Cardiometabolic Risk. American Journal of Cardiology, 2007, 100, S3-S6.	1.6	23
45	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
46	The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation. Cellular Signalling, 2019, 61, 20-29.	3.6	20
47	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2389-2398.	4.4	19
48	Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 656-669.	2.4	17
49	Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE ^{-/-} mice. International Journal of Cardiology, 2016, 223, 428-432.	1.7	15
50	Extensive metabolic disorders are present in APC ^{min} tumorigenesis mice. Molecular and Cellular Endocrinology, 2016, 427, 57-64.	3.2	15
51	Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 458-464.	2.1	15
52	Effect of lipid-lowering therapy on vasomotion and endothelial function. Current Cardiology Reports, 1999, 1, 238-243.	2.9	14
53	Intact vitamin A transport is critical for cold-mediated adipose tissue browning and thermogenesis. Molecular Metabolism, 2020, 42, 101088.	6.5	14
54	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American Journal of Preventive Cardiology, 2021, 8, 100278.	3.0	14

#	ARTICLE	IF	CITATIONS
55	Lipids in RA: Is Less Not Necessarily More?. <i>Current Rheumatology Reports</i> , 2018, 20, 8.	4.7	13
56	BRD2 regulation of sigma-2 receptor upon cholesterol deprivation. <i>Life Science Alliance</i> , 2021, 4, e201900540.	2.8	13
57	Expansion and contraction: the mighty, mighty fatty acid. <i>Nature Medicine</i> , 2009, 15, 618-619.	30.7	10
58	Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR α . <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S12-S14.	2.0	9
59	Retinaldehyde dehydrogenase 1 deficiency inhibits PPAR α -mediated bone loss and marrow adiposity. <i>Bone</i> , 2014, 67, 281-291.	2.9	8
60	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e12-e14.	1.8	8
61	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. <i>American Heart Journal</i> , 2022, 243, 15-27.	2.7	8
62	Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β 2-adrenergic receptor signaling. <i>PLoS ONE</i> , 2017, 12, e0173823.	2.5	8
63	Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1406-1413.	1.5	7
64	Predictors of a successful statin reattempt after an adverse reaction. <i>Journal of Clinical Lipidology</i> , 2018, 12, 643-651.	1.5	7
65	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 130-133.	1.6	7
66	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	4.2	7
67	Shortwave infrared spatial frequency domain imaging for non-invasive measurement of tissue and blood optical properties. <i>Journal of Biomedical Optics</i> , 2022, 27, .	2.6	7
68	To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa. <i>Journal of Global Health</i> , 2020, 10, 010407.	2.7	6
69	Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells. <i>Circulation Research</i> , 2022, 130, 1662-1681.	4.5	6
70	Impact of coronary artery calcium testing on patient management. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 303-308.	1.3	5
71	Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects. <i>Clinical Endocrinology</i> , 2018, 88, 388-396.	2.4	4
72	Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4

#	ARTICLE	IF	CITATIONS
73	Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. Journal of Heart and Lung Transplantation, 2014, 33, 215-217.	0.6	3
74	Epigenetic Therapeutics for Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2020, 323, 1557.	7.4	3
75	(Mis)interpreting studies on the adverse effects of statins. BMJ, The, 2014, 348, g3652-g3652.	6.0	2
76	The Aging Aorta: Are We Only as Old as Our Endothelium?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 172-174.	2.4	1
77	PPARs in Atherosclerosis. , 0, , 401-417.		0
78	Peroxisome Proliferator-Activated Receptors and the Endothelium. , 2007, , 796-805.		0
79	Emerging Epigenetic Maps in Atherosclerosis. Circulation: Cardiovascular Genetics, 2014, 7, 573-575.	5.1	0
80	Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 3457-3457.	1.4	0
81	Diabetes as a vascular disease. Dyslipidemia as a target. Postgraduate Medicine, 2003, 113, 15-23.	2.0	0